Summit Therapeutics Inc (SMMT)
$18.61
Performance
- $18.39$19.20$18.61
1.18%
Downside
Day's Volatility :4.24%
Upside
3.1%
- $1.64$33.89$18.61
91.19%
Downside
52 Weeks Volatility :95.16%
Upside
45.09%
Returns
| Period | Summit Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 157.04% | 5.7% | 0.0% |
6 Months | 425.71% | 6.7% | 0.0% |
1 Year | 933.89% | 18.4% | 0.0% |
3 Years | 263.48% | 20.8% | -20.2% |
Highlights
Market Capitalization | 17.6B |
Book Value | $0.27 |
Earnings Per Share (EPS) | -0.11 |
PEG Ratio | 0.0 |
Wall Street Target Price | 23.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -31.01% |
Return On Equity TTM | -102.77% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 705.0K |
EBITDA | -143.6M |
Diluted Eps TTM | -0.11 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.27 |
EPS Estimate Next Year | -0.3 |
EPS Estimate Current Quarter | -0.06 |
EPS Estimate Next Quarter | -0.07 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 26.28%
Technicals Summary
Sell
Neutral
Buy
Summit Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Summit Therapeutics Inc | 55.08% | 425.71% | 933.89% | 263.48% | 440.99% |
 Regeneron Pharmaceuticals, Inc. | -13.97% | 8.28% | 24.49% | 82.67% | 258.6% |
 Novo Nordisk A/s | -14.46% | -7.16% | 29.25% | 137.43% | 348.48% |
 Alnylam Pharmaceuticals, Inc. | 6.47% | 77.93% | 59.32% | 38.21% | 249.95% |
 Vertex Pharmaceuticals Incorporated | -5.23% | 12.26% | 28.5% | 155.67% | 163.05% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Summit Therapeutics Inc | 26.36 | NA | 0.0 | -0.27 | -1.03 | -0.31 | NA | 0.27 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Summit Therapeutics Inc | Buy | $17.6B | 440.99% | 26.36 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 258.6% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 348.48% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 249.95% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.05% | 32.84 | -4.74% |
Insights on Summit Therapeutics Inc
Decreasing Revenue
Revenue is down for the last 3 quarters, 235.0K → -235.0K (in $), with an average decrease of 100.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 8 quarters, -14.71M → -60.38M (in $), with an average decrease of 24.9% per quarter
Institutional Holdings
Baker Bros Advisors LP
3.21%Vanguard Group Inc
1.22%BlackRock Inc
1.09%FMR Inc
1.04%State Street Corp
0.57%Geode Capital Management, LLC
0.41%
Company Information
summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.
Organization | Summit Therapeutics Inc |
Employees | 105 |
CEO | Mr. Robert W. Duggan |
Industry | Health Technology |
Discover More
Xenon Pharmaceuticals Inc
$18.61
-4.76%
Brookfield Renewable Partners L.p.
$18.61
-4.76%
Brady Corp
$18.61
-4.76%
Liberty Global Plc - Class C Shares
$18.61
-4.76%
Dropbox, Inc.
$18.61
-4.76%
Element Solutions Inc
$18.61
-4.76%
Japan Hedged Equity Wisdomtree Etf
$18.61
-4.76%
Ero Copper Corp
$18.61
-4.76%
International Seaways, Inc.
$18.61
-4.76%